Allogene Therapeutics Announces Participation in December Investor Conferences

Company Overview - Allogene Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune diseases [3] - The company aims to provide "off-the-shelf" CAR T cell product candidates that are readily available on-demand, more reliably, and at greater scale to a larger patient population [3] Upcoming Events - Allogene will participate in two investor conferences in December 2024, including the Citizens JMP Hematology and Oncology Summit on December 2 and the 36th Annual Piper Sandler Healthcare Conference on December 3 [2] - The presentation time for the Jefferies London Healthcare Conference on November 20, 2024, has been updated to 11:30 AM GMT / 6:30 AM ET [2] Communication and Accessibility - Webcasts of the presentations will be available on the company's website under the Investors tab in the News and Events section, with replays accessible for approximately 30 days [2]